Back to Search
CARA JAKOB, MD
MD
Family Medicine Physician
NPI: 1376564542IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
ME0074002(FL)
Education
OTHER
Class of 1996
Research & Publications (20)
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
PMID 19614956·Eur J Haematol·2009
4-observational
Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
PMID 19067746·Eur J Haematol·2009
8-other
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
PMID 19410573·Exp Cell Res·2009
8-other
Htm1 protein generates the N-glycan signal for glycoprotein degradation in the endoplasmic reticulum.
PMID 19124653·J Cell Biol·2009
8-other
Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.
PMID 19258212·Eur J Med Res·2009
8-other
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase.
PMID 18766375·J Cancer Res Clin Oncol·2009
8-other
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
PMID 18331598·Eur J Haematol·2008
8-other
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
PMID 18580957·Leukemia·2008
4-observational
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
PMID 18005386·Eur J Haematol·2008
8-other
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
PMID 18286688·World J Gastroenterol·2008
8-other
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
PMID 18722050·Cancer Lett·2008
3-trial
A potent erythropoietin-mimicking human antibody interacts through a novel binding site.
PMID 17620453·Blood·2007
7-preclinical
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
PMID 17095627·Blood·2007
8-other
Transport of Na(+) and K (+) by an antiporter-related subunit from the Escherichia coli NADH dehydrogenase I produced in Saccharomyces cerevisiae.
PMID 17583799·Arch Microbiol·2007
8-other
Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.
PMID 17607924·Recent Results Cancer Res·2007
6-review
4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.
PMID 17197188·Bioorg Med Chem·2007
7-preclinical
Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
PMID 16403626·Bioorg Med Chem Lett·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3115 CITRUS TOWER BLVD, SUITE A
CLERMONT, FL 34711 - Phone
- (352) 394-4237
Quick Facts
- NPI
- 1376564542
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 30
- Publications
- 20
Are you this provider?
Claim Your Profile